Ramucirumab (IMC-1121B)

BIOLOGICAL6 trials

Sponsors

Eli Lilly and Company

Conditions

Breast CancerColorectal CarcinomaHepatocellular CarcinomaMalignant Solid TumorSolid Tumors

Phase 1

A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)

CompletedNCT01286818

Eli Lilly and CompanyColorectal Carcinoma

Start: 2011-02-28End: 2012-03-31Updated: 2014-10-06

Phase 2

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

CompletedNCT00627042

Eli Lilly and CompanyHepatocellular Carcinoma

Start: 2008-02-29End: 2011-05-31Updated: 2014-10-08

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

CompletedNCT01427933

Eli Lilly and CompanyBreast Cancer

Start: 2011-11-30End: 2014-06-30Updated: 2017-02-06

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

CompletedNCT01515306

Eli Lilly and CompanyMalignant Solid Tumor

Start: 2012-07-19End: 2021-02-22Updated: 2022-03-08

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

CompletedNCT01634555

Eli Lilly and CompanySolid Tumors

Start: 2012-10-31End: 2018-02-28Updated: 2019-02-26

Phase 3

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

CompletedNCT00703326

Eli Lilly and CompanyBreast Cancer

Start: 2008-08-06End: 2020-11-19Updated: 2021-12-06

Related Papers

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

2017-12-0189 citations

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.

2017-08-0155 citations

Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors.

Journal of Clinical Oncology2015-01-204 citations

Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).

Journal of Clinical Oncology2014-05-2016 citations

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of paclitaxel (PTX) and the PK of RAM as monotherapy in patients (pts) with advanced malignant solid tumors.

Journal of Clinical Oncology2014-05-202 citations